Alerts will be sent to your verified email
Verify Email
MAHAREM
|
IndoAmerican Advance
|
Krebs Biochem.&Inds
|
Bafna Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-12.16 % | 56.46 % | -52.11 % |
|
5yr average Equity Multiplier
|
1.07 | -2.97 | 3.77 |
|
5yr Average Asset Turnover Ratio
|
0.15 | 0.3 | 0.42 |
|
5yr Avg Net Profit Margin
|
-36.65 % | -60.0 % | -36.55 % |
|
Price to Book
|
n/a | 0.0 | 3.52 |
|
P/E
|
n/a | 0.0 | 41.81 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | -861.42 Days | 0.18 Days |
|
Inventory Days
|
0.0 | 115.42 Days | 87.65 Days |
|
Days Receivable
|
0.0 | 8.79 Days | 132.64 Days |
|
Days Payable
|
167.71 Days | 408.94 Days | 210.48 Days |
|
5yr Average Interest Coverage Ratio
|
-55.68 | -5.02 | -5.68 |
|
5yr Avg ROCE
|
-12.15 % | -22.06 % | -11.61 % |
|
5yr Avg Operating Profit Margin
|
-72.03 % | -38.55 % | -21.98 % |
|
5 yr average Debt to Equity
|
0.0 | -2.12 | 1.41 |
|
5yr CAGR Net Profit
|
n/a | -7.31 % | 12.0 % |
|
5yr Average Return on Assets
|
-11.02 % | -17.59 % | -16.11 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.97 % | 72.74 % | 75.0 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-17.4 % | 0.0 | -15.42 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
IndoAmerican Advance
|
Krebs Biochem.&Inds
|
Bafna Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|